Harm reduction for the treatment of patients with severe injection-related infections: description of the Jackson SIRI Team

被引:21
作者
Serota, David P. [1 ]
Tookes, Hansel E. [1 ]
Hervera, Belen [1 ]
Gayle, Babley M. [2 ]
Roeck, Cara R. [2 ]
Suarez, Edward [1 ]
Forrest, David W. [3 ]
Kolber, Michael A. [1 ]
Bartholomew, Tyler S. [3 ]
Rodriguez, Allan E. [1 ]
Doblecki-Lewis, Susanne [1 ]
机构
[1] Univ Miami, Dept Med, Div Infect Dis, Miller Sch Med, 1120 NW 14th St,Suite 851, Miami, FL 33136 USA
[2] Jackson Mem Hosp, Jackson Hlth Syst, Miami, FL 33136 USA
[3] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA
基金
美国国家卫生研究院;
关键词
Endocarditis; substance use disorder; skin and soft tissue infection; opioid use disorder; OPIOID USE DISORDER; DRUG-USE; MEDICATIONS; DISEASE; FLORIDA;
D O I
10.1080/07853890.2021.1993326
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Hospitalizations for severe injection-related infections (SIRI), such as endocarditis, osteomyelitis, and skin and soft tissue infections (SSTI) are increasingly common. People who inject drugs (PWID) experiencing SIRIs often receive inadequate substance use disorder (SUD) treatment and lack of access to harm reduction services. This translates into lengthy hospitalizations with high rates of patient-directed discharge, readmissions, and post-hospitalization mortality. The purpose of this study was to describe the development of an integrated "SIRI Team" and its initial barriers and facilitators to success. Materials and methods The Jackson SIRI Team was developed to improve both hospital and patient-level outcomes for individuals hospitalized with SIRIs at Jackson Memorial Hospital, a 1550-bed public hospital in Miami, Florida, United States. The SIRI Team provides integrated infectious disease and SUD treatment across the healthcare system starting from the inpatient setting and continuing for 90-days post-hospital discharge. The team uses a harm reduction approach, provides care coordination, focuses on access to medications for opioid use disorder (MOUD), and utilizes a variety of infection and addiction treatment modalities to suit each individual patient. Results Over the initial 8-months of the SIRI Team, 21 patients were treated with 20 surviving until discharge. Infections included osteomyelitis, endocarditis, bacteraemia/fungemia, SSTIs, and septic arthritis. All patients had OUD and 95% used stimulants. All patients were discharged on MOUD and 95% completed their prescribed antibiotic course. At 90-days post-discharge, 25% had been readmitted and 70% reported taking MOUD. Conclusions A model of integrated infectious disease and SUD care for the treatment of SIRIs has the potential to improve infection and addiction outcomes. Providing attentive, patient-centered care, using a harm reduction approach can facilitate engagement of this marginalized population with the healthcare system. KEY MESSAGES Integrated infectious disease and addiction treatment is a novel approach to treating severe injection-related infections. Harm reduction should be applied to treating patients with severe injection-related infections with a goal of facilitating antibiotic completion, remission from substance use disorder, and reducing hospital readmissions.
引用
收藏
页码:1960 / 1968
页数:9
相关论文
共 42 条
  • [1] Long-term Infective Endocarditis Mortality Associated With Injection Opioid Use in the United States: A Modeling Study
    Barocas, Joshua A.
    Yazdi, Golnaz Eftekhari
    Savinkina, Alexandra
    Nolen, Shayla
    Savitzky, Caroline
    Samet, Jeffrey H.
    Englander, Honora
    Linas, Benjamin P.
    [J]. CLINICAL INFECTIOUS DISEASES, 2021, 73 (11) : E3661 - E3669
  • [2] Impact of medications for opioid use disorder among persons hospitalized for drug use-associated skin and soft tissue infections
    Barocas, Joshua A.
    Gai, Mam Jarra
    Amuchi, Brenda
    Jawa, Raagini
    Linas, Benjamin P.
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2020, 215
  • [3] Outcomes Associated With Medications for Opioid Use Disorder Among Persons Hospitalized for Infective Endocarditis
    Barocas, Joshua A.
    Morgan, Jake R.
    Wang, Jianing
    McLoone, Dylan
    Wurcel, Alysse
    Stein, Michael D.
    [J]. CLINICAL INFECTIOUS DISEASES, 2021, 72 (03) : 472 - 478
  • [4] Blevins SR., 2020, OPEN FORUM INFECT DI, V7, pS173
  • [5] Hospital admissions among people who inject opioids following syringe services program implementation
    Bornstein, K. J.
    Coye, A. E.
    St Onge, J. E.
    Li, H.
    Muller, A.
    Bartholomew, T. S.
    Tookes, H. E.
    [J]. HARM REDUCTION JOURNAL, 2020, 17 (01)
  • [6] When is an abscess more than an abscess? Syringe services programs and the harm reduction safety-net: a case report
    Castillo, Marcus
    Ginoza, Margaret E. C.
    Bartholomew, Tyler S.
    Forrest, David W.
    Greven, Cestaki
    Serota, David P.
    Tookes, Hansel E.
    [J]. HARM REDUCTION JOURNAL, 2020, 17 (01)
  • [7] Hospital Costs of Injection Drug Use in Florida
    Coye, Austin E.
    Bornstein, Kasha J.
    Bartholomew, Tyler S.
    Li, Hua
    Wong, Stanley
    Janjua, Naveed Z.
    Tookes, Hansel E.
    St Onge, Joan E.
    [J]. CLINICAL INFECTIOUS DISEASES, 2021, 72 (03) : 499 - 502
  • [8] Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science
    Damschroder, Laura J.
    Aron, David C.
    Keith, Rosalind E.
    Kirsh, Susan R.
    Alexander, Jeffery A.
    Lowery, Julie C.
    [J]. IMPLEMENTATION SCIENCE, 2009, 4
  • [9] We Thought We Created a Safety Net. We Were Wrong
    Eaton, Ellen F.
    [J]. CLINICAL INFECTIOUS DISEASES, 2021, 73 (07) : E1658 - E1660
  • [10] Inpatient Addiction Medicine Consultation and Post-Hospital Substance Use Disorder Treatment Engagement: a Propensity-Matched Analysis
    Englander, Honora
    Dobbertin, Konrad
    Lind, Bonnie K.
    Nicolaidis, Christina
    Graven, Peter
    Dorfman, Claire
    Korthuis, P. Todd
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2019, 34 (12) : 2796 - 2803